Navigation Links
Mindray Announces 2008 Fourth Quarter and Full Year Results
Date:3/4/2009

tion, operating results, prospects, and business outlook for fiscal year 2009, customer acceptance of company products, continued R&D spending levels, increased headcounts, growth in the company's business segments and geographies, business execution, growth in medical spending and the factors driving that growth, international expansion, integration of a recently acquired business, introduction of new products, expansion into new geographic markets and localizing our distribution teams, our ability to gain market share, our ability to control costs, and our ability to cross sell products. These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. The financial information contained i
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Mindray Medical International Announces Second Quarter 2008 Results
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. Mindray Medical International Announces First Quarter 2008 Results
4. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
5. Mindray Medical International Announces Third Quarter 2007 Results
6. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
7. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
8. Martek Announces First Quarter 2009 Financial Results
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... With a larger, brighter interface, ... Cole-Parmer® Digital Gear Pump Drive for Micropump® ... for automated process applications. , Simply set time ... count function counts down and displays batches completed ... dispensed across multiple cycles. View the four operating ...
(Date:7/21/2014)... (July 21, 2014) The yield so far ... have developed a low-energy, solution-based mineral substitution process to ... find use in electronics and alternative energy devices. , ... cover of the July 21 issue of the journal ... of research in the inorganic and nuclear chemistry fields. ...
(Date:7/21/2014)... Sleep disturbances such as insomnia, hypersomnia, ... depression. According to a study published by the ... of depressed patients have insomnia symptoms, and hypersomnia ... adults and 10% of older patients, with a ... have a major impact on quality of life, ...
(Date:7/19/2014)... 20, 2014 United States Non-Vascular ... GlobalDatas new report, "United States Non-Vascular Stents Market ... the United States Non-Vascular Stents market. The report ... (in units) and average prices (in US dollars) ... Stents and Metal Biliary Stents (Metal Non-Covered Biliary ...
Breaking Biology Technology:New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Oregon chemists eye improved thin films with metal substitution 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today ... ended December 31, 2008."2008 was a transition year for ... focused on lower-risk reformulations of previously-approved drugs. We achieved ... the difficult economic environment, we were unable to attract ...
... Insmed Inc. (Nasdaq: INSM ), a developer of ... March 23, 2009, NASDAQ issued a notice further extending the ... price and those rules requiring a minimum market value of ... effect through Friday, July 17, 2009, and the original rules ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... patient enrolment in its U.K. clinical trial to ... REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients ... neck. The principal investigators are Dr. Johann de ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:7/22/2014)... -- Stem cells offer much promise for treating damaged ... cell survival is poor, limiting their effectiveness. New methods ... and optimize their therapeutic function after transplantation, as described ... , a peer-reviewed journal from Mary Ann Liebert, Inc., ... BioResearch Open Access website . , ...
(Date:7/22/2014)... research has shown squirrels have adapted to New York ... well, if not better, than their fellow squirrels in ... Curtin,s Department of Environment & Agriculture, led the study ... their behaviour in urban environments and prevent unnecessary responses ... staying on the footpath. , "As we rapidly ...
(Date:7/22/2014)... of meerkats which sees them prevent their daughters from ... new study. , Research into the desert creatures which ... adult helpers shows that the alpha female can flourish ... study shows how this way of life, also found in ... despite its sinister side. , Dominant meerkats control breeding ...
Breaking Biology News(10 mins):New York squirrels are nuts about city life 2
... novel,vaccine that uses immune cells as factories to produce ... breast cancers, say researchers at,The University of Texas M. ... is a protein often present / surexpressed in ... Breast Cancer Research,on Nov. 29, 2004, showed that the ...
... NGEN), developer of advanced diagnostic products, announced today that ... Biologic Array" by the U.S. Patent and Trademark Office. ... one or more electrodes (or "test sites") across multiple ... covers a method for storing the value of the ...
... the Dana-Farber Cancer Institute report a surprising finding about ... only in the embryo itself, but also in the ... , Meticulous experiments in mice revealed that the placenta ... These cells, which appear very early in development, are ...
Cached Biology News:Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 2Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 3Nanogen Issued Patent for Electronic Microarray With Memory 2Placenta Is A Rich Source Of Blood Stem Cells 2
... anti-phospho-IRS1 (Tyr896) ... amino acid region encompassing the ... (Tyr896). Accession ... Quality Assurance: Routinely ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
CCNI Antibody...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Biology Products: